Doximity Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Doximity wird ein jährliches Gewinn- und Umsatzwachstum von 13.3% bzw. 11.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 9.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 21.3% betragen.

Wichtige Informationen

13.3%

Wachstumsrate der Gewinne

9.7%

EPS-Wachstumsrate

Healthcare Services Gewinnwachstum	23.7%
Wachstumsrate der Einnahmen	11.2%
Zukünftige Eigenkapitalrendite	21.3%
Analystenabdeckung	Good
Zuletzt aktualisiert	15 Apr 2025

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Earnings Not Telling The Story For Doximity, Inc. (NYSE:DOCS) After Shares Rise 34%

Nov 13

Does This Valuation Of Doximity, Inc. (NYSE:DOCS) Imply Investors Are Overpaying?

Nov 02

Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?

Oct 15

Doximity: Downgrade To Hold On Valuation Concerns

Oct 03

Here's Why Doximity (NYSE:DOCS) Has Caught The Eye Of Investors

Sep 23

Generative AI And Digital Health Innovations Fuel Robust Revenue Growth And Market Expansion

Aug 28 Accelerating adoption of new products and a client portal, alongside strategic positioning with top clients, suggests sustained revenue expansion.

There's Reason For Concern Over Doximity, Inc.'s (NYSE:DOCS) Massive 27% Price Jump

Aug 18

Doximity (NYSE:DOCS) Looks To Prolong Its Impressive Returns

Aug 10

Doximity Faces Slower Revenue Growth As R&D Costs May Rise

Jul 23

Is Doximity, Inc. (NYSE:DOCS) Trading At A 23% Discount?

Jul 23

At US$27.97, Is It Time To Put Doximity, Inc. (NYSE:DOCS) On Your Watch List?

Jul 01

Optimistic Investors Push Doximity, Inc. (NYSE:DOCS) Shares Up 26% But Growth Is Lacking

Jun 09

Doximity Earnings: Better Than Expected, But Still Mixed Outlook (Rating Upgrade)

May 17

Capital Allocation Trends At Doximity (NYSE:DOCS) Aren't Ideal

May 04

Doximity: Significant Upside Remains, But Not Until The Growth Story Returns

Apr 29

Doximity: Rating Upgrade To Buy As Outlook Turns Positive

Feb 21

Doximity: Downside Is Contained, While Upside Depends On Management's Game Plan

Jan 16

Doximity Earnings: Steer Clear Of This Rollercoaster War Of Optimism Vs. Skepticism

Nov 10

Doximity: Adding Value Using AI But Faces Near-Term Risks

Nov 01

Doximity: Rating Downgrade As Investors Shift Focus To The Near-Term Outlook

Aug 24

Doximity Earnings: Too Many Problems, Sell

Aug 09

Doximity: Continue To See Positive Upside From Current Stock Level

Jul 05

Gewinn- und Umsatzwachstumsprognosen

NYSE:DOCS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2028	806	326	364	372	3
3/31/2027	715	265	319	328	13
3/31/2026	640	227	292	292	19
3/31/2025	570	200	259	269	19
12/31/2024	550	201	232	239	N/A
9/30/2024	517	174	217	224	N/A
6/30/2024	494	161	162	168	N/A
3/31/2024	475	148	178	184	N/A
12/31/2023	468	138	162	167	N/A
9/30/2023	448	123	160	165	N/A
6/30/2023	437	119	186	192	N/A
3/31/2023	419	113	173	180	N/A
12/31/2022	402	119	173	180	N/A
9/30/2022	384	141	151	159	N/A
6/30/2022	362	148	131	138	N/A
3/31/2022	344	133	121	127	N/A
12/31/2021	317	107	113	117	N/A
9/30/2021	277	57	110	114	N/A
6/30/2021	243	30	103	107	N/A
3/31/2021	207	22	78	83	N/A
12/31/2020	177	14	48	53	N/A
3/31/2020	116	11	22	26	N/A
3/31/2019	86	1	14	15	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: DOCSDas prognostizierte Gewinnwachstum (13.3% pro Jahr) liegt über der Sparquote (2.8%).

Ertrag vs. Markt: DOCSDie Erträge des Unternehmens (13.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (13.3% pro Jahr).

Hohe Wachstumserträge: DOCSDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: DOCSDie Einnahmen des Unternehmens (11.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.1% pro Jahr).

Hohe Wachstumseinnahmen: DOCSDie Einnahmen des Unternehmens (11.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: DOCSDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (21.3%)

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2025/04/22 14:17
Aktienkurs zum Tagesende	2025/04/22 00:00
Gewinne	2024/12/31
Jährliche Einnahmen	2024/03/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Doximity, Inc. wird von 27 Analysten beobachtet. 19 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Vikram Kesavabhotla	Baird
Nisala Weerasuriya	Berenberg
Allen Lutz	BofA Global Research

Doximity Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 27% to US$70.06

Doximity, Inc. Provides Earnings Guidance for the Fiscal Fourth Quarter Ending March 31, 2025 and Updates Earnings Guidance for the Fiscal Year Ending March 31, 2025

Doximity, Inc. Provides Earnings Guidance for Its Fiscal Third Quarter Ending December 31, 2024 and Updating Earnings Guidance for Its Fiscal Year Ending March 31, 2025

Price target increased by 8.5% to US$37.21

Price target increased by 7.1% to US$31.64

Doximity, Inc. Provides Revenue Guidance for the Second Quarter Ending September 30, 2024 and Fiscal Year Ending March 31, 2025

Recent updates

Shareholders Are Optimistic That Doximity (NYSE:DOCS) Will Multiply In Value

What Doximity, Inc.'s (NYSE:DOCS) 28% Share Price Gain Is Not Telling You

Co-Founder recently sold US$62m worth of stock

Investor sentiment improves as stock rises 29%

Doximity Q3 Earnings: Outpacing Even Management's Expectations

Price target increased by 27% to US$70.06

Now 24% overvalued after recent price rise

Doximity, Inc. Provides Earnings Guidance for the Fiscal Fourth Quarter Ending March 31, 2025 and Updates Earnings Guidance for the Fiscal Year Ending March 31, 2025

Independent Director notifies of intention to sell stock

When Should You Buy Doximity, Inc. (NYSE:DOCS)?

Doximity, Inc. to Report Q3, 2025 Results on Feb 06, 2025

Now 21% overvalued after recent price rise

Doximity: Upgraded To Buy Amid Promising Growth And Strong Execution

Here's Why We Think Doximity (NYSE:DOCS) Is Well Worth Watching

Now 24% overvalued after recent price rise

Doximity: Strong Fundamentals And Growth Potential Makes It Attractive

Doximity (NYSE:DOCS) Knows How To Allocate Capital

Investor sentiment improves as stock rises 20%

Chief Financial Officer notifies of intention to sell stock

Earnings Not Telling The Story For Doximity, Inc. (NYSE:DOCS) After Shares Rise 34%

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. Provides Earnings Guidance for Its Fiscal Third Quarter Ending December 31, 2024 and Updating Earnings Guidance for Its Fiscal Year Ending March 31, 2025

Independent Director notifies of intention to sell stock

Does This Valuation Of Doximity, Inc. (NYSE:DOCS) Imply Investors Are Overpaying?

Doximity, Inc. to Report Q2, 2025 Results on Nov 07, 2024

Price target increased by 8.5% to US$37.21

Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?

Doximity: Downgrade To Hold On Valuation Concerns

Here's Why Doximity (NYSE:DOCS) Has Caught The Eye Of Investors

Now 22% overvalued after recent price rise

Generative AI And Digital Health Innovations Fuel Robust Revenue Growth And Market Expansion

There's Reason For Concern Over Doximity, Inc.'s (NYSE:DOCS) Massive 27% Price Jump

Investor sentiment improves as stock rises 39%

Chief Financial Officer exercised options and sold US$1.1m worth of stock

Price target increased by 7.1% to US$31.64

Doximity (NYSE:DOCS) Looks To Prolong Its Impressive Returns

New minor risk - Share price stability

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. Provides Revenue Guidance for the Second Quarter Ending September 30, 2024 and Fiscal Year Ending March 31, 2025

Doximity Faces Slower Revenue Growth As R&D Costs May Rise

Is Doximity, Inc. (NYSE:DOCS) Trading At A 23% Discount?

Doximity, Inc., Annual General Meeting, Aug 29, 2024

Doximity, Inc. to Report Q1, 2025 Results on Aug 08, 2024

Now 29% undervalued

Now 28% undervalued

At US$27.97, Is It Time To Put Doximity, Inc. (NYSE:DOCS) On Your Watch List?

Now 22% undervalued after recent price drop

Chief Financial Officer notifies of intention to sell stock

Optimistic Investors Push Doximity, Inc. (NYSE:DOCS) Shares Up 26% But Growth Is Lacking

Investor sentiment improves as stock rises 18%

Doximity, Inc. Provides Financial Guidance for the First Quarter Ending June 30, 2024 and Full Year Ending March 31, 2025

Full year 2024 earnings released: EPS: US$0.78 (vs US$0.58 in FY 2023)

Doximity Earnings: Better Than Expected, But Still Mixed Outlook (Rating Upgrade)

Doximity, Inc. (NYSE:DOCS) announces an Equity Buyback for $500 million worth of its shares.

Capital Allocation Trends At Doximity (NYSE:DOCS) Aren't Ideal

Doximity: Significant Upside Remains, But Not Until The Growth Story Returns

Doximity, Inc. to Report Q4, 2024 Results on May 16, 2024

Kessler Topaz Meltzer & Check, LLP Files Securities Fraud Class Action Lawsuit Against Doximity, Inc

Doximity: Rating Upgrade To Buy As Outlook Turns Positive

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ending March 31, 2024

Price target increased by 7.2% to US$28.17

Doximity, Inc. to Report Q3, 2024 Results on Feb 08, 2024

Doximity: Downside Is Contained, While Upside Depends On Management's Game Plan

Now 21% undervalued

Investor sentiment improves as stock rises 24%

Doximity, Inc. Provides Revenue Guidance for the Fiscal Third Quarter Ending December 31, 2023 and Fiscal Year Ending March 31, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. (NYSE:DOCS) announces an Equity Buyback for $70 million worth of its shares.